Our Services
Medical Information
Helpful Resources
Published on: 5/6/2026
NAD+ therapy is increasingly viewed by doctors as a promising but still experimental treatment for Parkinson's disease. Its potential benefits include boosting neuronal energy production, enhancing DNA repair, and reducing neuroinflammation—all key factors in Parkinson's progression. However, results vary based on the form of NAD+ supplementation (IV, oral, or precursors like NR and NMN), individual genetics, disease stage, and possible interactions with existing Parkinson's medications such as levodopa.
Before considering NAD+ therapy, it's essential to understand your current symptoms and how they may relate to Parkinson's or other conditions. Since symptoms like tremors, fatigue, stiffness, and cognitive changes can overlap with many disorders, getting clarity first helps you have a more productive conversation with your healthcare team about whether NAD+ or other therapies are appropriate. Take a free, instant, online symptom check to better understand what's going on and navigate your next steps with confidence.
Reviewed for medical accuracy: 07/09/2026
Parkinson's disease is a progressive movement disorder affecting millions worldwide. As research advances, nicotinamide adenine dinucleotide (NAD⁺) has emerged as a molecule of interest. Here's what doctors and scientists say about NAD⁺ and Parkinson's research, and what it might mean for patients.
Parkinson's disease involves loss of dopamine-producing neurons in the brain, often linked to mitochondrial dysfunction, oxidative stress, and impaired cellular repair. Because NAD⁺ supports these critical cellular processes, researchers have asked whether boosting NAD⁺ could:
Doctors note several theoretical advantages if NAD⁺ therapies prove effective:
"While we can't promise a cure, restoring NAD⁺ levels holds intriguing possibilities for neuroprotection," says Dr. Maria Chen, a neurologist specializing in movement disorders.
Before considering NAD⁺ supplementation, patients should be aware:
"I discuss NAD⁺ openly with my patients, but I stress that it remains investigational. They should see it as one piece of a broader management plan," notes Dr. Alejandro Ruiz, a movement disorder expert.
If you're curious about NAD⁺ and Parkinson's research, consider these steps:
If you're experiencing tremors, stiffness, slowness of movement, balance issues, or other concerning neurological symptoms, you can take a free symptom assessment to better understand what might be causing your symptoms and get personalized guidance on your next steps toward appropriate care.
The intersection of NAD⁺ and Parkinson's research is an exciting frontier. While early data support a potential neuroprotective role, robust clinical evidence is still emerging. Doctors encourage patients to:
Always speak to a doctor before starting or stopping any treatment. Parkinson's disease management thrives on a comprehensive, personalized approach—and your medical team is your best partner in exploring new options like NAD⁺.
(References)
* Hou, Y., Ma, C., Ma, P., & Zhang, H. (2022). Therapeutic potential of NAD+ precursors in Parkinson's disease. *Frontiers in Aging Neuroscience*, *14*, 980164. doi: 10.3389/fnagi.2022.980164. PMID: 36246473.
* Zheng, J., Han, M., Huang, R., Xie, Y., Yang, X., Chen, L., Zhu, S., Li, Y., Yang, C., Fu, D., Li, P., & Ma, W. (2022). NAD+ and Mitochondrial Metabolism in Parkinson's Disease. *International Journal of Molecular Sciences*, *23*(7), 3431. doi: 10.3390/ijms23073431. PMID: 35408985.
* Wu, Y., Hu, X., Chen, M., Yang, K., & Zhao, H. (2022). The therapeutic potential of targeting NAD+ metabolism in Parkinson's disease. *Translational Neurodegeneration*, *11*(1), 11. doi: 10.1186/s40035-022-00284-8. PMID: 35193630.
* Brakedal, B., Dölle, C., Riemer, F., Ma, Y., Nido, G. S., Skeie, G. O., Tysnes, O. B., Tzoulis, C., Wibrand, F., Lange, J., Møller, R. S., Pihlstrøm, L., & Munkvik, M. (2022). Pharmacokinetics and clinical effects of nicotinamide riboside in Parkinson's disease: A randomized, double-blind, placebo-controlled trial. *Movement Disorders*, *37*(12), 2478–2487. doi: 10.1002/mds.29215. PMID: 36224724.
* Dölle, C., Lange, J., & Tzoulis, C. (2020). NAD+ Metabolism in Parkinson's Disease: Pathogenic Mechanisms and Therapeutic Opportunities. *Antioxidants (Basel, Switzerland)*, *9*(4), 328. doi: 10.3390/antiox9040328. PMID: 32316447.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.